GSK3B and glioma: Furthermore, it has been demonstrated that AZD2858 (a GSK3β inhibitor) induces the nuclear accumulation of β-catenin, reducing the proliferation and invasion in glioma cells through of upregulation of p53, which regulates the transcription of p21, the Fas ligand, and caspase-3 31, as well as the downregulation of proteins involved in cell adhesion and cell migration, like collagen type I, Laminin, CD44, and fibronectin 31.